Alector Reports First Quarter 2026 Financial Results and Provides Business Update
Rhea-AI Summary
Alector (Nasdaq: ALEC) reported Q1 2026 results and a business update on May 7, 2026. Cash, cash equivalents, and investments were $206.5 million as of March 31, 2026, which management expects will fund operations at least through 2027. The company advanced its Alector Brain Carrier (ABC) platform across antibodies, enzymes, and siRNA, highlighted IND-targeting timelines (AL037/AL137 targeted for Q1 2027), ongoing preclinical progress for AL050 and AL164, and discontinuation of the PROGRESS-AD Phase 2 nivisnebart trial after a prespecified interim futility analysis.
Q1 financials: collaboration revenue $1.0M, R&D $17.9M, G&A $8.1M, net loss $22.9M (≈$0.21/share).
Positive
- Cash runway of $206.5M expected through 2027
- R&D expenses decreased to $17.9M in Q1 2026
- AL037/AL137 targeted for an IND submission in Q1 2027
- AL164 (tau siRNA) advancing into IND-enabling studies after robust NHP data
Negative
- PROGRESS-AD Phase 2 nivisnebart trial discontinued for interim futility
- Collaboration revenue fell to $1.0M in Q1 2026 from $3.7M
- Net loss remained $22.9M for Q1 2026 despite improvement year-over-year
Key Figures
Market Reality Check
Peers on Argus
Peer moves are mixed: FHTX (-0.64%), CAPR (+3.74%), LCTX (-4.36%), MNPR (+12.13%), OMER (+0.41%). Momentum scanner only flags LCTX with a modest upside move, suggesting today’s setup is stock-specific rather than a broad biotech rotation.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 25 | Earnings update | Positive | +7.1% | Q4 2025 results, ABC platform progress, and cash runway through 2027. |
| Nov 06 | Earnings update | Negative | -1.5% | Q3 2025 results plus discontinuation of latozinemab Phase 3 program. |
| Aug 07 | Earnings update | Positive | +47.3% | Q2 2025 results, strong cash position, and late-stage trial timelines. |
| May 08 | Earnings update | Positive | +12.5% | Q1 2025 results, substantial cash and guidance reaffirmed for 2025. |
| Feb 26 | Earnings update | Positive | -3.5% | Q4 2024 results with improved loss and detailed 2025 guidance. |
Earnings releases have often produced sizable moves, with mostly positive reactions but one notable negative divergence.
Recent earnings updates have emphasized Alector’s ABC platform and cash runway, with prior cash balances of $413.4M (Q4 2024), $354.6M (Q1 2025), $307.3M (Q2 2025), $291.1M (Q3 2025), and $256.0M (Q4 2025). These reports also highlighted major clinical milestones and guidance. Historically, earnings headlines have triggered moves both up and down, with an average absolute move of about 12.37%, underscoring event-driven trading around financial updates.
Historical Comparison
Over the past five earnings releases, ALEC’s average 24-hour move was 12.37%. Today’s roughly 0% move contrasts with that history, indicating a comparatively muted reaction to this quarter’s update.
Earnings reports have shown a declining cash balance yet continued runway through 2026–2027, while ABC-enabled programs advanced from earlier IND-enabling work toward defined IND targets and highlighted shifts after key trial readouts.
Regulatory & Risk Context
An effective S-3 shelf dated March 12, 2026 allows Alector to offer up to $400,000,000 of various securities, with $308,196,683.14 carried forward from a prior registration and 0 recorded usages so far.
Market Pulse Summary
This announcement highlights reduced R&D and G&A spending, a smaller net loss of $22.9M (or $0.21 per share), and a cash position of $206.5M expected to fund operations through 2027. It underscores ongoing investment in the ABC brain-delivery platform and multiple preclinical programs after discontinuation of the nivisnebart Phase 2 trial. Investors may watch future cash trends, ABC program milestones, and any use of the $400,000,000 shelf registration.
Key Terms
siRNA medical
investigational new drug (IND) regulatory
enzyme replacement therapy (ERT) medical
tauopathies medical
Phase 2 medical
data monitoring committee medical
Rule 10b5-1 Trading Plan regulatory
AI-generated analysis. Not financial advice.
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer’s disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson’s disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)
SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devasting progression of neurodegeneration, today reported first quarter 2026 financial results and recent portfolio and business updates. As of March 31, 2026, Alector’s cash, cash equivalents, and investments totaled
“Over the past seven years, we have built a highly differentiated blood-brain barrier platform with the versatility to deliver antibodies, enzymes, proteins, and siRNA to the brain,” said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. “We have a rich and growing pipeline of ABC-enabled programs, and we remain deeply committed to developing therapies that can make a meaningful difference for patients living with neurodegenerative diseases.”
Recent Program Updates
Alector Brain Carrier (ABC): Preclinical and Research Pipeline
At the core of Alector’s strategy is the Alector Brain Carrier (ABC), the company’s proprietary platform designed to enhance the delivery of therapeutics to the brain. ABC is intended for peripheral dosing and is adaptable across multiple drug modalities, including antibodies, enzymes, and siRNA.
The platform is built on core design principles of versatility, optimized binding properties, and translatability, with the goal of achieving efficient and targeted brain delivery while maintaining a favorable safety profile. Across multiple ABC-enabled programs, preclinical studies have demonstrated robust brain penetration, supporting the advancement of a broad pipeline aimed at addressing the underlying drivers of neurodegenerative diseases.
AL037/AL137
- Alector continues to advance AL037/AL137, its ABC-enabled anti-amyloid beta (Aβ) antibody program for the treatment of AD, through investigational new drug (IND)-enabling studies. The company is targeting an IND submission in Q1 2027.
- Both of our AL037 and AL137 candidates are engineered for optimal brain uptake, potency, safety, and convenience. Both candidates comprise the same high-affinity, fully human antibody that selectively binds PyroGlu3, a validated epitope on toxic amyloid beta found in plaques and retain an active effector function intended to facilitate myeloid-mediated plaque clearance. AL037 and AL137 each incorporates Alector’s proprietary ABC technology with TfR binding domains that bind the same epitope on TfR, but with different affinities and binding kinetics, to balance brain penetration and plaque removal with minimized hematologic adverse effects.
AL050
- Alector continues to progress AL050, its ABC-enabled engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT) for PD, through preclinical development.
- AL050 is designed to address key challenges associated with enzyme delivery to the brain, featuring an engineered GCase with improved activity and stability and a silenced effector function to maximize safety, paired with Alector’s tunable ABC technology. Preclinical studies to date have demonstrated increased GCase activity and reduced toxic substrate accumulation, supporting its continued preclinical development as a potential therapy for PD and Lewy body dementia (LBD) associated with GBA loss-of-function mutations and subsequently for idiopathic PD and LBD. We continue to evaluate our timeline to the clinic.
ABC siRNA Platform
- Alector is advancing its ABC-enabled siRNA platform with the goal of making treatment more accessible by enabling peripheral dosing as a potential alternative to traditional intrathecal delivery.
- Alector continues to advance AL064/AL164, its ABC-enabled tau siRNA program for the treatment of AD and other tauopathies. AL064 demonstrated robust tau mRNA knockdown and durable reduction of phospho-Tau 217 in non-human primate studies, and it was subsequently modified to further optimize siRNA stability. This modified form is advancing into IND-enabling studies as AL164.
- In addition to AL164, the company is advancing early-stage siRNA programs toward lead candidate selection, including ADP062-ABC, an alpha-synuclein siRNA for PD and ADP065-ABC, an NLRP3 siRNA for multiple neurodegenerative conditions, reflecting the broad applicability of the ABC platform across disease mechanisms.
Progranulin Program (nivisnebart (AL101/GSK4527226)
- The global, randomized, double-blind, placebo-controlled PROGRESS-AD Phase 2 clinical trial of nivisnebart (AL101/GSK4527226) in early AD has been discontinued following a pre-specified interim futility analysis. An independent data monitoring committee concluded that the trial was unlikely to meet its primary endpoint of slowing disease progression at completion. As the company’s platform and pipeline have continued to evolve, Alector remains focused on the significant opportunities ahead across its ABC-enabled programs.
First Quarter 2026 Financial Results
Revenue. Collaboration revenue for the quarter ended March 31, 2026, was
R&D Expenses. Total research and development expenses for the quarter ended March 31, 2026, were
G&A Expenses. Total general and administrative expenses for the quarter ended March 31, 2026, were
Net Loss. For the quarter ended March 31, 2026, Alector reported a net loss of
Cash Position. Cash, cash equivalents, and investments were
About Alector
Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as Alzheimer’s disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, research and preclinical pipeline, blood-brain barrier technology platform, planned and ongoing preclinical studies, expected milestones, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, with the Securities and Exchange Commission (“SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.
Selected Consolidated Balance Sheet Data
(in thousands)
| March 31, | December 31, | ||||
| 2026 | 2025 | ||||
| Cash, cash equivalents, and marketable securities | $ | 206,515 | $ | 256,024 | |
| Total assets | 239,916 | 293,237 | |||
| Total current liabilities (excluding deferred revenue) | 34,242 | 62,819 | |||
| Deferred revenue (including current portion) | 169,589 | 171,221 | |||
| Total liabilities | 229,534 | 262,588 | |||
| Total stockholders’ equity | 10,382 | 30,649 | |||
Condensed Consolidated Statement of Operations Data
(in thousands, except share and per share data)
Three Months Ended March 31, | |||||||
| 2026 | 2025 | ||||||
| Collaboration revenue | $ | 1,046 | $ | 3,674 | |||
| Operating expenses: | |||||||
| Research and development | 17,857 | 33,641 | |||||
| General and administrative | 8,108 | 14,728 | |||||
| Total operating expenses | 25,965 | 48,369 | |||||
| Loss from operations | (24,919 | ) | (44,695 | ) | |||
| Other income, net | 1,989 | 4,224 | |||||
| Loss before income taxes | (22,930 | ) | (40,471 | ) | |||
| Income tax expense | — | — | |||||
| Net loss | $ | (22,930 | ) | $ | (40,471 | ) | |
| Net loss per share, basic and diluted | $ | (0.21 | ) | $ | (0.41 | ) | |
| Shares used in computing net loss per share basic and diluted | 110,590,014 | 99,398,200 | |||||
Alector Contacts:
Argot Partners (media)
David Rosen
(646) 461-6387
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
(212) 600-1902
alector@argotpartners.com
